Internal Medicine
Systematic review: Among patients with advanced chronic kidney disease and uremic pruritus, gabapentinoids are the most studied treatments and show the greatest reduction in itch scores
13 Dec, 2020 | 23:16h | UTCInterventions for itch in people with advanced chronic kidney disease – Cochrane Library
Commentary: What is the best treatment for itch in people with chronic kidney disease? – Cochrane Library
Just published: Pfizer vaccine confers 95% protection against Covid-19
11 Dec, 2020 | 09:32h | UTCSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine – New England Journal of Medicine
Editorial: SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
Commentary: Pfizer vaccine results published in peer-reviewed journal – MedicalXpress
Related: FDA advisory panel endorses Pfizer/BioNTech Covid-19 vaccine – STAT
Commentary on Twitter (Thread – Click for more)
I read the @pfizer @US_FDA vaccine briefing doc
3 take homes (1 obvious, 2 new takes I haven't seen before)
1. Efficacy is great to prevent #COVID19 & promising for severe illness (this has been said many times before)
Moving on…https://t.co/WLrEpjmuO8
— Anil Makam (@AnilMakam) December 10, 2020
Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis
13 Dec, 2020 | 23:12h | UTCEditorial: Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?
Commentary: Budesonide for Maintaining EoE Remission – gutsandgrowth
Commentary on Twitter
In a phase 3 trial, up to 48 weeks of treatment with BOT was superior to placebo in maintaining remission of #EoE https://t.co/vewrFYgIG9 pic.twitter.com/P1DzdWb2vH
— Gastroenterology (@AGA_Gastro) November 25, 2020
Healthcare workers 7 times as likely to have severe COVID-19 as other workers
11 Dec, 2020 | 09:29h | UTCCommentary: Healthcare workers 7 times as likely to have severe COVID-19 as other workers – BMJ
Commentary on Twitter
Of essential workers, who has the highest risk of severe #COVID19?
Healthcare workforce >7X.
Non-white >8X.https://t.co/ZBUJYccXlT (compared with non-essential workers)
A @uk_biobank study from >120,000 participants
[NB: current issue with link] pic.twitter.com/UZmIO69G4O— Eric Topol (@EricTopol) December 9, 2020
Supplement: Lupus in the 21st Century
13 Dec, 2020 | 23:13h | UTCHomepage: Lupus in the 21st Century
Editorial: Lupus in the 21st century
- Classifying and diagnosing systemic lupus erythematosus in the 21st century
- New biomarkers in SLE: from bench to bedside
- Treatment targets in SLE: remission and low disease activity state
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
- Lupus nephritis: clinical presentations and outcomes in the 21st century
- The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?
- The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?
- Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Randomized trial: No difference in quality of life and slightly greater weight loss with Roux-en-Y Gastric Bypass compared to Laparoscopic Sleeve Gastrectomy at 7 years
11 Dec, 2020 | 09:20h | UTCEffect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss and Quality of Life at 7 Years in Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary: Using Quality-of-Life Measures to Determine the Ideal Bariatric Procedure – JAMA Surgery (free for a limited period)
WHO reveals leading causes of death and disability worldwide: 2000-2019
11 Dec, 2020 | 09:24h | UTCWHO reveals leading causes of death and disability worldwide: 2000-2019 – World Health Organization
Fact Sheet: The top 10 causes of death
Long Covid: Study shows persistence of symptoms in a third of ambulatory patients 30 to 45 days after diagnosis
11 Dec, 2020 | 09:27h | UTCCommentary: COVID-19: persistent symptoms in one third of cases – Université de Genève
Commentary on Twitter
Study of 669 people who had #COVID19 during the first wave in Switzerland. Of 510 who were followed up for 30-45 days, 32% still had at least one symptom.
Fatigue, shortness of breath, and loss of smell or taste were the most common symptoms. #LongCovidhttps://t.co/pDB6nuZWTn pic.twitter.com/bbt9c3LFXl
— Dr Zoë Hyde (@DrZoeHyde) December 8, 2020
Review: Mechanical complications of acute myocardial infarction
11 Dec, 2020 | 09:19h | UTCMechanical Complications of Acute Myocardial Infarction: A Review – JAMA Cardiology
Videos: Acute Rupture of Left Ventricular Aneurysm AND Ventricular Septal Rupture AND Papillary Muscle Rupture
British HIV Association guidelines on the management of gastrointestinal opportunistic infections in people living with HIV
11 Dec, 2020 | 09:16h | UTC
Systematic Review: Financial conflicts of interest are associated with favorable recommendations of drugs and devices in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews
11 Dec, 2020 | 09:18h | UTC
Global burden of cardiovascular diseases and risk factors, 1990–2019
10 Dec, 2020 | 09:00h | UTCNews Release: JACC: Cardiovascular Disease Burden, Deaths Are Rising Around the World – Institute for Health Metrics and Evaluation
Commentary on Twitter
https://twitter.com/IHME_UW/status/1336792746842058756
Systematic Review: Probiotics probably make little or no difference for patients with acute infectious diarrhea
10 Dec, 2020 | 08:53h | UTCProbiotics for treating acute infectious diarrhoea – Cochrane Library
Summary: Do probiotics help to treat acute infectious diarrhoea? – Cochrane Library
Systematic review: Men with COVID-19 have almost three times the risk of requiring ICU admission and a higher risk of death
10 Dec, 2020 | 08:45h | UTCCommentary: Men face ‘almost three times the odds’ of ICU admission for Covid-19, study says – CNN AND Men with COVID-19 three times more likely to need intensive care: study – MedicalXpress
Commentary on Twitter
Men w/ COVID19 are 3 times more likely to need intensive care & are at significantly higher risk of dying from the virus than women. New research analyzed over 3 million confirmed cases from 46 countries and 44 states. 2 links: https://t.co/g9nYKWxzcv
andhttps://t.co/ZOIfSYImWi— delthia ricks 🔬 (@DelthiaRicks) December 9, 2020
Randomized trial: In patients with recurrent, complicated, or persistent painful diverticulitis, sigmoid resection improved quality of life but was associated with a small but significant risk of major complications
10 Dec, 2020 | 08:51h | UTCAuthor Interview: Laparoscopic Sigmoid Resection vs Conservative Treatment in Improving Quality of Life in Diverticulitis
Commentary on Twitter
https://twitter.com/drferzli/status/1330948905941557248
A nationwide study in Denmark showed a higher than expected risk of cardiac events in patients with cancer receiving immune checkpoint inhibitors
10 Dec, 2020 | 08:49h | UTC
UK to refine allergy warning on Pfizer vaccine sparked by two adverse reactions
10 Dec, 2020 | 08:41h | UTCUK to refine allergy warning on Pfizer vaccine sparked by two adverse reactions – Reuters
See also: UK probes whether COVID-19 vaccine caused allergic reactions – Associated Press AND NHS told not to give Covid vaccine to those with history of allergic reactions – The Guardian
CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk
9 Dec, 2020 | 08:23h | UTCCDC Releases New Ventilation Guidelines For Indoor Environments To Reduce Covid-19 Risk – Forbes
CDC Guideline: Ventilation
Related podcast: Air Handling Standards for Increasing the Safety of Indoor Spaces During the COVID-19 Pandemic – JAMA
Just published: AstraZeneca-Oxford Covid-19 vaccine shows moderate efficacy, but questions remain about the most effective dosing regimen
9 Dec, 2020 | 08:25h | UTCCommentaries: Oxford COVID vaccine paper highlights lingering unknowns about results – Nature AND Detailed data on AstraZeneca-Oxford Covid-19 vaccine show it has moderate efficacy – STAT AND Oxford–AstraZeneca COVID-19 vaccine efficacy – The Lancet AND Oxford COVID-19 vaccine is safe and protects against disease, first published results from phase 3 trials – The Lancet AND Expert reaction to a study on the results of phase 3 human trials of the Oxford/AZ COVID-19 vaccine – Science Media Centre
“COVID-19: when are you most infectious?” This commentary from the authors of a recent meta-analysis highlights the findings that infectiousness peaks within the first 5 days of symptom onset
10 Dec, 2020 | 08:38h | UTCCOVID-19: when are you most infectious? – The Conversation
Original study and commentaries: Meta-analysis: SARSCoV2 most contagious within the first 5 days of symptom onset
“Neurological manifestations of COVID-19” – guideline of the German society of neurology
9 Dec, 2020 | 08:15h | UTC
Another randomized trial shows hydroxychloroquine is not effective as postexposure prophylaxis to prevent Covid-19
9 Dec, 2020 | 08:19h | UTCSummary for patients: Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection
Randomized trial: No benefit and potential harm from Vitamin D at doses of 1000 IU/d or higher compared with 200 IU/d in older persons with elevated fall risk
9 Dec, 2020 | 08:13h | UTCCommentaries: Study Finds No Benefit, Possible Harm to Seniors’ Fall Risks with Higher Doses of Vitamin D – Johns Hopkins Medicine AND Does High-Dose Vitamin D Actually Heighten Fall Risk? – Physician’s Weekly
Commentary on Twitter (thread – click for more)
https://twitter.com/ErinMichos/status/1336091776994537472
Cohort study: In the general population, both low and high levels of LDL cholesterol were associated with an increased risk of all-cause mortality
9 Dec, 2020 | 08:11h | UTC
Commentary on Twitter
Studies on the association between LDL-C levels and the risk of all cause mortality have provided conflicting results. This new study investigates the association between levels of LDL-C and the risk of all cause and cause specific mortalityhttps://t.co/phsKXIgPfq
— The BMJ (@bmj_latest) December 8, 2020
If exposed to Covid-19, how long before you have symptoms? Median incubation is 5.1 days, and 97.5% of those who develop symptoms do so within 11.5 days of being exposed to the virus
8 Dec, 2020 | 08:06h | UTCIf Exposed To Covid-19 Coronavirus, How Long Before You Have Symptoms – Forbes